Altimmune (ALT) reported a net loss of $31.6 million, or $0.15 per basic and diluted share, for the third quarter ended September 30, 2026. The company reported no revenue for the quarter and held $480 million in cash, cash equivalents and investments at quarter-end.
Research and development expense rose to $27.0 million from $15.0 million a year earlier, while general and administrative expense increased to $8.7 million from $5.9 million. Altimmune said its global PERFORMA Phase 3 trial in MASH is progressing as planned.
- R&D expenses included $20.3 million of direct pemvidutide development costs.
- Interest income was $4.8 million in the quarter.
- PERFORMA 52-week topline data are anticipated in 2029.
- An FDA End-of-Phase 2 meeting for pemvidutide in alcohol use disorder is scheduled for December 2026.
- RESTORE Phase 2 topline data in alcohol-associated liver disease are expected in the second half of 2027.
$ALT Insider Trading Activity
$ALT insiders have traded $ALT stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ALT stock by insiders over the last 6 months:
- JEROME BENEDICT DURSO (President and CEO) purchased 15,000 shares for an estimated $44,250
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$ALT Hedge Fund Activity
We have seen 117 institutional investors add shares of $ALT stock to their portfolio, and 83 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DEEP TRACK CAPITAL, LP added 19,250,000 shares (+inf%) to their portfolio in Q2 2026, for an estimated $58,520,000
- TCG CROSSOVER MANAGEMENT, LLC added 10,000,000 shares (+inf%) to their portfolio in Q2 2026, for an estimated $30,400,000
- BLACKROCK, INC. added 7,590,007 shares (+59.3%) to their portfolio in Q2 2026, for an estimated $23,073,621
- VIKING GLOBAL INVESTORS LP added 6,700,000 shares (+inf%) to their portfolio in Q2 2026, for an estimated $20,368,000
- RA CAPITAL MANAGEMENT, L.P. added 6,500,000 shares (+inf%) to their portfolio in Q2 2026, for an estimated $19,760,000
- STATE STREET CORP removed 3,742,132 shares (-30.9%) from their portfolio in Q3 2026, for an estimated $10,702,497
- WOODLINE PARTNERS LP added 3,400,312 shares (+inf%) to their portfolio in Q2 2026, for an estimated $10,336,948
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.